Wuhan Boye Technology Development Co., Ltd. is a national high-tech enterprise specializing in the research, development, and industrialization of specialty active pharmaceutical ingredients (APIs), key starting materials, and pharmaceutical intermediates. The company is committed to establishing a leading pharmaceutical and chemical service platform in China, making pharmaceutical and chemical R&D more efficient and environmentally friendly. Over the years, it has consistently served the pharmaceutical field, accumulating leading R&D technological capabilities domestically and continuously providing services to well-known pharmaceutical companies and research institutions both in China and abroad.

The company and its subsidiary, Jiangxi Boye Pharmaceutical Technology Co., Ltd., mainly engage in the following products: (1) Specialty APIs and pharmaceutical intermediates, including Plerixafor and its key intermediates; (2) Pesticide intermediates and liquid crystal material intermediates, such as thiadiazole and triphenylphosphine, which have been sold worldwide and received high praise from customers; (3) Key impurities of APIs, including Esomeprazole impurities, Mesalazine impurities, Memantine hydrochloride impurities, Paclitaxel impurities, among others; (4) Other chemical intermediates and the operation of hazardous chemicals.

Adhering to the advanced cultural philosophy of "Quality First, Integrity as the Foundation, Customer Service, and Technological Innovation," Boye strictly follows international standards in its quality management system, maintains standardized product supply management, and continuously improves its service system. It is dedicated to providing high-quality products and services for global drug research, development, and production.